EASL 2018 FRI-320 PEG-IFN增加或改变HBsAg清除的作用 HBeAg-CHB患者接

StephenW

EASL 2018 FRI-320
The effect of PEG-IFN add on or switch to on HBsAg clearance in
HBeAg- CHB patients recieving entecavir treatment
L. Yan, Y. Xu, L. Chen, Y. Ding, Q. Xie, H. Wang. Shanghai Jiaotong
University School, Department of Infectious Diseases and Hepatology,
Shanghai, China
Email: [email protected]
Background and Aims: Chronic hepatitis B (CHB) patients rarely
achieve HBsAg loss with nucleoside/nucleotide analogue (NA)
therapy. It was evaluated HBsAg loss in HBeAg− patients with
entecavir switched to or added on pegylated interferon (PEG-IFN) in a
retrospective study.
Method: Totally 87 HBeAg− CHB patients treated with entecavir for
24weekswere studied, 21 switched to PEG-IFN,13 added on PEG-IFN
and 53 continued entecavir therapy (ETV group).
Results: HBsAg clearance at week 48 was reported in 2/21 (10%)
patients in switch-to group, 2/13 (15%) patients in add-on group;
whereas none was in ETV group. HBsAg reduction at week 48 was
1.055logIU/ml, 0.6452 logIU/ml or 0.014 logIU/ml respectively in
switch-to, add-on, or ETV group. The response rate of switch-to, addon
and ETV monotherapy was, 44%, 38% or 2%, respectively. It was
analysed that age, BMI, ALT, AST, PLT, liver stiffness, HBsAg titer at
baseline, or HBsAg reduction at 24-week, showing that HBsAg titers at
baseline and HBsAg reduction atweek 24were associatedwith HBsAg
reduction and clearance. HBsAg reduction was associated with the
response rate atweek24, showing thatROCCurve analyse the response
versus HBsAg atweek 48, the AUROCwas 0.865. The PPV for response
was 70% and NPV was 100% with the cut-off value 0.2logIU/ml.
Conclusion: In summary, we demonstrated that PEG-IFN enhanced
HBsAg loss in HBeAg−CHB population. Patients with HBsAg titers at
baseline less than 1000 IU/ml and HBsAg reduction more than
0.2logIU/ml achieved HBsAg loss with a higher chance.

StephenW

EASL 2018 FRI-320
PEG-IFN增加或改变HBsAg清除的作用
HBeAg-CHB患者接受恩替卡韦治疗
L. Yan，Y. Xu，L. Chen，Y. Ding，Q. Xie，H. Wang。上海交通
大学学院，传染病与肝病学系，
上海，中国
电子邮件：[email protected]
背景和目标：慢性乙型肝炎（CHB）患者很少
用核苷/核苷酸类似物（NA）实现HBsAg消失
治疗。评估了HBeAg-患者HBsAg消失的情况
恩替卡韦改用聚乙二醇干扰素（PEG-IFN）或加入聚乙二醇干扰素（PEG-IFN）
回顾性研究。
方法：恩替卡韦治疗HBeAg-CHB共87例
24周研究，21转换为PEG-IFN，13加到PEG-IFN上
和53持续恩替卡韦治疗（ETV组）。
结果：第48周的HBsAg清除率为2/21（10％）
切换组患者，2/13（15％）患者在附加组;
而ETV组则没有。第48周时HBsAg的降低是
1.055logIU / ml，0.6452logIU / ml或0.014logIU / ml
切换，附加组件或ETV组。切换至的附加响应速率
和ETV单药治疗分别为44％，38％或2％。它是
分析了年龄，BMI，ALT，AST，PLT，肝硬度，HBsAg滴度
基线或24周时HBsAg降低，表明HBsAg滴度在24周
HBsAg的基线和HBsAg下降与第24周相关
减少和清除。乙型肝炎表面抗原减少与乙型肝炎相关
响应率atweek24，显示了ROCCurve分析响应
与48周时的HBsAg相比，AUROC为0.865。响应的PPV
为70％，NPV为100％，临界值为0.2logIU / ml。
结论：总之，我们证明了PEG-IFN增强
HBeAg-CHB人群HBsAg消失。乙肝表面抗体滴度达标的患者
基线低于1000 IU / ml且HBsAg降低更多
0.2logIU / ml达到HBsAg消失的几率较高。

齐欢畅

Hepbest

EASL 2018 FRI-320
The effect of PEG-IFN add on or switch to on HBsAg clearance in HBeAg- CHB patients recieving entecavir treatment
L. Yan, Y. Xu, L. Chen, Y. Ding, Q. Xie, H. Wang. Shanghai Jiaotong University School, Department of Infectious Diseases and Hepatology,
Shanghai, China
Email: [email protected]

Background and Aims:
Chronic hepatitis B (CHB) patients rarely achieve HBsAg loss with nucleoside/nucleotide analogue (NA) therapy. It was evaluated HBsAg loss in HBeAg− patients with entecavir switched to or added on pegylated interferon (PEG-IFN) in a retrospective study.

Method:
Totally 87 HBeAg− CHB patients treated with entecavir for 24weekswere studied, 21 switched to PEG-IFN,13 added on PEG-IFN and 53 continued entecavir therapy (ETV group).

Results:
HBsAg clearance at week 48 was reported in 2/21 (10%) patients in switch-to group, 2/13 (15%) patients in add-on group; whereas none was in ETV group. HBsAg reduction at week 48 was 1.055logIU/ml, 0.6452 logIU/ml or 0.014 logIU/ml respectively in switch-to, add-on, or ETV group. The response rate of switch-to, addon
and ETV monotherapy was, 44%, 38% or 2%, respectively. It was analysed that age, BMI, ALT, AST, PLT, liver stiffness, HBsAg titer at baseline, or HBsAg reduction at 24-week, showing that HBsAg titers at baseline and HBsAg reduction atweek 24were associatedwith HBsAg reduction and clearance. HBsAg reduction was associated with the response rate atweek24, showing thatROCCurve analyse the response versus HBsAg atweek 48, the AUROCwas 0.865. The PPV for response was 70% and NPV was 100% with the cut-off value 0.2logIU/ml.

Conclusion:  
In summary, we demonstrated that PEG-IFN enhanced HBsAg loss in HBeAg−CHB population. Patients with HBsAg titers at baseline less than 1000 IU/ml and HBsAg reduction more than 0.2logIU/ml achieved HBsAg loss with a higher chance.

Hepbest

EASL 2018 FRI-320
接受恩替卡韦治疗的HBeAg-CHB患者中PEG-IFN对HBsAg清除的增加或改变作用
L. Yan，Y. Xu，L. Chen，Y. Ding，Q. Xie，H. Wang。上海交通大学传染病与肝病研究所，
上海，中国
电子邮件：[email protected]

背景和目标：
慢性乙型肝炎（CHB）患者很少用核苷/核苷酸类似物（NA）治疗获得HBsAg消失。在回顾性研究中评估了恩替卡韦转换为或加入聚乙二醇干扰素（PEG-IFN）的HBeAg患者HBsAg消失。

方法：
共研究87例接受恩替卡韦治疗24周的HBeAg-CHB患者，21例改用PEG-IFN，13例加用PEG-IFN，53例继续使用恩替卡韦治疗（ETV组）。

结果：
在转换组中2/21（10％）患者，在附加组中2/13（15％）患者中报道48周时HBsAg清除率;而ETV组则没有。 48周时HBsAg降低分别为1.055logIU / ml，0.6452logIU / ml或0.014logIU / ml，在转换，添加或ETV组中。切换至的附加响应速率
和ETV单药治疗分别为44％，38％或2％。分析了24周时的年龄，体重指数，ALT，AST，PLT，肝硬度，HBsAg滴度或HBsAg下降情况，结果显示HBsAg滴度在24周时与HBsAg降低和清除相关。 HBsAg下降与周24的应答率相关，表明RRCurve在48周时分析了对HBsAg的应答，AUROC为0.865。响应的PPV为70％，NPV为100％，截止值为0.2logIU / ml。

结论：
总之，我们证明了PEG-IFN增加了HBeAg-CHB人群中的HBsAg消失。基线时HBsAg滴度低于1000IU / ml且HBsAg降低超过0.2logIU / ml的患者实现HBsAg消失的可能性更高。